Carol Giltner Gallagher
CIK 1329959 · SVP, Corp Dev & Comm Affairs · last filed 2026-10-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ATRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DEL MAR, CA 92104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRXB | Director | — | — | — | $0 | 1 | 2026-10-08 |
| PMVP | Director | — | $1.13 | — | $0 | 5 | 2026-06-05 |
| ATRA | Director | 35,518 | $8.35 | $296.6K | -$1.99M | 30 | 2025-06-12 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | 6,808 | $58.70 | $399.6K | $0 | 3 | 2024-01-23 |
| Frazier Lifesciences Acquisition Corp (FLACW) Delisted | Director | — | $0.80 | — | $0 | 1 | 2022-11-23 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| CERT | Director | 7,059 | $10.61 | $74.9K | $0 | 1 | 2021-06-16 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 2,129 | $15.90 | $33.9K | $0 | 4 | 2020-06-23 |
| ANAB | Director | 64,296 | $48.77 | $3.14M | $0 | 3 | 2018-02-06 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | SVP, Corp Dev & Comm Affairs | — | — | — | $0 | 1 | 2007-05-18 |
Recent Filings · Page 2 of 6
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-12 | PMVP | Mixed | — | $0 | EDGAR |
| 2023-06-02 | ATRA | Grant (A) | +57,000 | $0 | EDGAR |
| 2022-11-23 | Frazier Lifesciences Acquisition Corp (FLACW) Delisted | Exer (M) | — | $0 | EDGAR |
| 2022-11-08 | PMVP | Mixed | — | $0 | EDGAR |
| 2022-08-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-06-27 | ATRA | Grant (A) | +20,500 | $0 | EDGAR |
| 2021-06-16 | CERT | Grant (A) | +7,059 | $0 | EDGAR |
| 2021-06-09 | ATRA | Grant (A) | +11,000 | $0 | EDGAR |
| 2021-06-04 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-23 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.